DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Bailard Inc.

Bailard Inc. trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 57,707 shares of the medical device company’s stock after selling 756 shares during the period. Bailard Inc.’s holdings in DexCom were worth $3,941,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Geode Capital Management LLC increased its position in shares of DexCom by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company’s stock worth $775,256,000 after acquiring an additional 56,094 shares during the last quarter. Norges Bank acquired a new stake in DexCom during the 4th quarter valued at $385,367,000. Northern Trust Corp increased its stake in shares of DexCom by 22.2% in the fourth quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company’s stock worth $322,454,000 after acquiring an additional 753,857 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in DexCom by 171.0% during the first quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company’s stock worth $218,175,000 after buying an additional 2,015,971 shares during the last quarter. Finally, Artisan Partners Limited Partnership grew its position in shares of DexCom by 12.2% in the fourth quarter. Artisan Partners Limited Partnership now owns 1,853,565 shares of the medical device company’s stock valued at $144,152,000 after purchasing an additional 201,181 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Transactions at DexCom

In related news, Director Nicholas Augustinos sold 3,672 shares of the company’s stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $82.80, for a total value of $304,041.60. Following the transaction, the director owned 33,411 shares in the company, valued at approximately $2,766,430.80. This represents a 9.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sadie Stern sold 1,466 shares of the business’s stock in a transaction on Thursday, June 26th. The shares were sold at an average price of $85.06, for a total transaction of $124,697.96. Following the transaction, the executive vice president owned 108,155 shares of the company’s stock, valued at $9,199,664.30. This trade represents a 1.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 27,190 shares of company stock worth $2,281,732. Insiders own 0.32% of the company’s stock.

DexCom Price Performance

DXCM opened at $84.10 on Friday. The stock has a market cap of $32.98 billion, a price-to-earnings ratio of 62.76, a PEG ratio of 1.79 and a beta of 1.44. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $116.35. The company has a current ratio of 1.50, a quick ratio of 1.32 and a debt-to-equity ratio of 0.55. The stock has a fifty day moving average price of $84.51 and a 200 day moving average price of $80.13.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. The firm’s revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the company earned $0.32 earnings per share. Analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Ratings Changes

DXCM has been the subject of several research analyst reports. Morgan Stanley boosted their price objective on shares of DexCom from $82.00 to $89.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Canaccord Genuity Group increased their price target on shares of DexCom from $103.00 to $106.00 and gave the stock a “buy” rating in a research report on Friday, May 2nd. The Goldman Sachs Group started coverage on shares of DexCom in a report on Friday, May 30th. They set a “buy” rating and a $104.00 price target on the stock. Citigroup reissued a “buy” rating and set a $102.00 target price (up previously from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Finally, Robert W. Baird reduced their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.60.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.